Combination antimuscarinics and alpha-blockers for benign prostatic hyperplasia.

Abstract

Millions of men suffer from lower urinary tract symptoms and overactive bladder. The adverse effects on quality of life and the costs associated with the condition have been well described. Although alpha-adrenergic antagonists have long been considered first-line therapy for male lower urinary tract symptoms, many patients have persistent storage symptoms and do not reach their treatment goal. Increasing data and clinical experience support the efficacy and safety of anticholinergics in men, either as monotherapy or in combination with alpha-blockers.

• Authors: Scott A MacDiarmid
• Journal: Current urology reports (Curr Urol Rep) Vol. 9 Issue 4 Pg. 265-71 (Jul 2008) ISSN: 1534-6285 [Electronic] United States
• PMID: 18765124 (Publication Type: Journal Article, Review)

Chemical References

• Adrenergic alpha-Antagonists
• Muscarinic Antagonists

Topics

• Adrenergic alpha-Antagonists (administration & dosage)
• Drug Therapy, Combination
• Humans
• Male
• Muscarinic Antagonists (administration & dosage)
• Prostatic Hyperplasia (drug therapy)